Walmart testing same-day delivery for holidays
BENTONVILLE, Ark. — Walmart said Tuesday it is testing same-day delivery service in four markets over the holiday shopping season.
The service is being tested in northern Virginia, Philadelphia, Minneapolis and San Francisco/San Jose, Calif. Geared toward customers who buy popular items online during the holidays, the test includes about 5,000 items and builds on a same-day grocery delivery service the retailer launched in San Jose in April 2010 and tested in San Francisco in 2011.
According to Walmart spokeswoman Amy Lester, the company has no immediate plans to roll out the service to other stores. "This is truly to learn and better understand what our customers want," Lester said.
To use the service, customers can place orders up until noon and then choose a four-hour window to receive the delivery the same day. Walmart is using UPS delivery trucks to deliver the merchandise. For the San Francisco and San Jose markets, shoppers have to order by 7 a.m. that day to receive those items. Walmart is using its own delivery trucks in those two regions.
Mylan settles suit over asthma, allergy drug
PITTSBURGH — Mylan has settled a patent infringement suit over a drug used to treat respiratory diseases, Mylan said.
The generic drug maker said it resolved a patent litigation suit filed by Shionogi and Cima Labs over prednisolone sodium phosphate orally disintegrating tablets, a generic version of Orapred ODT. Mylan is hoping to market its generic version of the drug in the 10-mg, 15-mg and 30-mg strengths. The drug is used to treat asthma and certain allergic conditions.
Under the settlement, Mylan will be able to launch its product starting in April 2014. The company said it was likely the first company to file a regulatory approval application containing a Paragraph IV certification, a legal assertion that the patent covering the branded drug is invalid, unenforceable or not at risk of being infringed.
Orapred ODT had sales of $33.1 million during the 12-month period ended in June, according to IMS Health.
Shopko names interim CEO
GREEN BAY, Wis. — Shopko announced Wednesday that Mike Bettiga has been named interim CEO to replace Paul Jones, who resigned to pursue another opportunity.
Bettiga is a 35-veteran of the company and most recently served as EVP and COO, a role he has held since April 2009. He began his career with Shopko as a pharmacist in 1977, and has held a number of positions during his tenure, including executive leadership of store, pharmacy and optical operations, retail health merchandising and responsibility for the Shopko Express stores.
"I am grateful for the opportunity to serve as Interim CEO for Shopko, a company that I have been an integral part of for most of my professional career," Bettiga said. "We have ambitious plans for the future, including the continued rollout of the Shopko Hometown concept and I look forward to leading the team on that effort and our other growth initiatives."
In December 2011, Bettiga testified on behalf of the National Association of Chain Drug Stores before the Senate Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights against the ESI-Medco merger.
"We appreciate the many contributions Paul Jones has made to Shopko during the past five years and wish him nothing but the best," said Scott King, senior managing director of Sun Capital Partners, a leading private investment firm whose affiliate owns Shopko. King noted that a national search is under way to select a new leader for the company.
As reported earlier this year, Shopko merged with retailer Pamida, converting all of the latter’s stores to the Shopko Hometown format. Over the summer, the company also had appointed a new SVP and general merchandise manager of home and hardlines and expanded the role of its SVP product development to become responsible for overseeing the retailer’s consumables division.